Evidence map›Paper›PMID 27837436›Full record

ReviewJournal of neuro-oncology2017

Withaferin A and its potential role in glioblastoma (GBM).

Jasdeep Dhami, Edwin Chang, Sanjiv S Gambhir

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Differential Effects ofIntegrative cancer therapies
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jasdeep DhamiHealth Sciences Center, Texas Tech University, El Paso, TX, USA.
Edwin ChangDepartment of Radiology, Molecular Imaging Program at Stanford and Canary Center at Stanford for Early Cancer Detection, Stanford University, Palo Alto, CA, USA.
Sanjiv S GambhirDepartment of Radiology, Molecular Imaging Program at Stanford and Canary Center at Stanford for Early Cancer Detection, Stanford University, Palo Alto, CA, USA. sgambhir@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Within the Ayurvedic medical tradition of India, Ashwagandha (Withania somnifera) is a well-known herb. A large number of withanolides have been isolated from both its roots and its leaves and many have been assessed for their pharmacological activities. Amongst them, Withaferin A is one of its most bioactive phytoconstituents. Due to the lactonal steroid's potential to modulate multiple oncogenic pathways, Withaferin A has gained much attention as a possible anti-neoplastic agent. This review focuses on the use of Withaferin A alone, or in combination with other treatments, as a newer option for therapy against the most aggressive variant of brain tumors, Glioblastoma. We survey the various studies that delineate Withaferin A's anticancer mechanisms, its toxicity profiles, its pharmacokinetics and pharmacodynamics and its immuno-modulating properties.

Indexed as

Antineoplastic AgentsBrain NeoplasmsGlioblastomaHumansTreatment OutcomeWithanolidesAntineoplastic Agentswithaferin AWithanolidesAnticancerAshwagandhaGlioblastomaImmunomodulationOncogenic pathwaysPharmacodynamicsPharmacokineticsPharmacologicalWithaferin AWithania somniferaWithanolides

Identifiers

PMID27837436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.